BEAM Stock Risk & Deep Value Analysis
Beam Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About BEAM Stock
We analyzed Beam Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran BEAM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
BEAM Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is clinical failure: if lead base editing programs, particularly BEAM-101 or BEAM-302, fail to demonstrate sufficient efficacy or safety in ongoing or future trials, the company's valuation could plummet. Additionally, the lack of detailed financial visibility creates uncertainty regarding cash runway and potential dilutive financing needs.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Critical absence of detailed Q1 2026 financial and balance sheet data, hindering assessment of cash runway and burn rate.
- ⚠
No reported analyst consensus, price targets, or institutional ownership data, limiting external validation and sentiment insights.
- ⚠
Insider sales, though routine for tax purposes, are not balanced by any discretionary insider buys, which could signal stronger conviction.
Upcoming Risk Events
- 📅
Negative or inconclusive results from ongoing clinical trials
- 📅
Regulatory delays or outright rejection of key therapeutic candidates
- 📅
Need for additional dilutive capital raises if cash burn accelerates
When to Reconsider
- 🚪
Failure of a pivotal clinical trial (e.g., BEAM-101) to meet primary endpoints.
- 🚪
Significant negative regulatory feedback or clinical hold on a lead program.
- 🚪
Announcement of a highly dilutive capital raise that substantially reduces per-share value.
Unlock BEAM Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Beam Therapeutics Inc (BEAM) Do?
Market Cap
$2.42B
Sector
Healthcare
Industry
Biotechnology
Employees
509
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Visit Beam Therapeutics Inc WebsiteInvestment Thesis
Beam Therapeutics is a leading innovator in base editing, a groundbreaking gene editing technology poised to revolutionize the treatment of genetic diseases. With promising clinical data for BEAM-101 and active pipeline expansion (BEAM-302, BEAM-304), Beam is strategically positioned for future market leadership. The company's proprietary technology offers a strong competitive advantage, potentially delivering 10x growth as its pipeline matures and de-risks, despite the inherent financial and clinical uncertainties of an early-stage biotech.
Is BEAM Stock Undervalued?
Unlock the full AI analysis for BEAM
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
BEAM Price Targets & Strategy
12-Month Target
$42.00
Bull Case
$60.00
Bear Case
$15.00
Valuation Basis
Based on successful execution of near-term clinical milestones and market re-rating of lead assets, reaching a valuation of ~1.7x current market cap.
Entry Strategy
Consider dollar-cost averaging in the $22-$25 range, especially on any dips towards recent support levels or the 52-week low if macro conditions are unfavorable.
Exit Strategy
Take partial profits at $40-$45; reassess after major clinical readouts. Set a stop-loss order below the 52-week low ($13.53) or if lead clinical programs face significant setbacks.
Portfolio Allocation
7-15% for aggressive risk tolerance, reflecting the high-risk, high-reward nature of early-stage biotech.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is BEAM Financially Healthy?
Profitability
Operating Margin
-837.12%
Net Margin
-744.41%
Return on Equity
-47.19%
Revenue Growth
280.30%
EPS
$-4.42
Balance Sheet
Current Ratio
13.09
Debt/Equity
0.20
Total Debt
$151.42M
Cash & Equivalents
$1.07B
Cash Flow
Operating Cash Flow
-$345.00M
EBITDA
-$444.22M
Other
Beta (Volatility)
2.12
Does BEAM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is strengthening as clinical programs advance and validate the base editing platform. Its durability depends on continued scientific leadership, successful clinical outcomes, and the ability to maintain IP protection against emerging competitors or alternative gene editing modalities.
Moat Erosion Risks
- •Emergence of competing gene editing technologies with superior efficacy or safety profiles.
- •Challenges to Beam's intellectual property by competitors or regulatory bodies.
- •Failure to achieve clinical success, undermining the value of the proprietary technology.
BEAM Competitive Moat Analysis
Sign up to see competitive advantages
BEAM Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (stock down 13.6% YTD, but up 77% from 52-week low indicates mixed but underlying interest).
Institutional Sentiment
Neutral (no data available on analyst ratings or institutional ownership shifts).
Insider Activity (Form 4)
CEO John M. Evans sold 30,078 shares ($739,115) on April 1, 2026 (tax-related 10b5-1 plan). SVP Finance Bethany J. Cavanagh sold 3,242 shares ($79,688) on April 1, 2026 (tax-related). CMO Amy Simon sold 6,700 shares ($164,686) on March 31, 2026 (tax-related). President Giuseppe Ciaramella sold 11,810 shares ($290,290) (tax-related). No discretionary insider buys reported.
Options Flow
Normal options activity (no specific unusual options activity data provided).
Earnings Intelligence
Next Earnings
2026-05-12
Surprise Probability
Medium
Historical Earnings Pattern
Cannot be assessed due to lack of historical data on earnings reactions.
Key Metrics to Watch
Competitive Position
Top Competitor
No data available on key competitors from provided research.
Market Share Trend
Not applicable at this early stage; focus is on technology validation and pipeline development.
Valuation vs Peers
Cannot be assessed due to lack of valuation metrics and peer data.
Competitive Advantages
- •Proprietary base editing technology offering high precision and potentially superior safety profile.
- •Extensive intellectual property portfolio in the gene editing space.
- •First-mover advantage in specific base editing applications.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive BEAM Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings on May 12, 2026 (updates on pipeline and financial health expected)
- •Further clinical updates or interim data from BEAM-101 (sickle cell disease)
- •Initiation of additional clinical trials or expansion of existing ones
Medium-Term (6-18 months)
- •IND filing for BEAM-304 (PKU program) expected in 2026
- •Potential strategic partnerships for pipeline assets or technology licensing
- •Advancement of BEAM-302 (AATD gene therapy) into later-stage trials
Long-Term (18+ months)
- •Commercialization of lead base editing therapies, particularly BEAM-101
- •Expansion of base editing platform into a broader range of genetic diseases
- •Disruption of traditional gene therapy market with superior precision and safety
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for BEAM?
- ✓
Consistent positive clinical trial readouts for BEAM-101 and BEAM-302.
- ✓
Strategic partnerships that validate the technology and provide non-dilutive funding.
- ✓
Clear progress toward commercialization for lead assets and robust intellectual property defense.
Bull Case Analysis
See what could go right with Premium
Competing with BEAM
See how Beam Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Beam Therapeutics Inc BEAM | $2.4B | 9.1 | — | $55.7M | -744.4% | 280.3% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Beam Therapeutics Inc Makes Money
Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. This novel gene-editing approach chemically modifies individual DNA bases without making double-strand breaks, aiming for safer and more precise corrections of disease-causing genetic mutations. The company identifies genetic diseases with high unmet medical needs, develops therapeutic candidates through rigorous R&D and clinical trials, and aims to generate revenue through successful regulatory approvals, commercialization of its drugs, or strategic licensing agreements with larger pharmaceutical partners.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Beam Therapeutics Inc (BEAM)?
As of April 7, 2026, Beam Therapeutics Inc has a DVR Score of 9.1 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Beam Therapeutics Inc?
Beam Therapeutics Inc's market capitalization is approximately $2.4B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Beam Therapeutics Inc use?
BEAM is the ticker symbol for Beam Therapeutics Inc. The company trades on the NMS.
What is the risk level for BEAM stock?
Our analysis rates Beam Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Beam Therapeutics Inc's revenue growing?
Beam Therapeutics Inc has reported revenue growth of 280.3%. The company is showing strong top-line momentum.
Is BEAM stock profitable?
Beam Therapeutics Inc has a profit margin of -744.4%. The company is currently unprofitable.
How often is the BEAM DVR analysis updated?
Our AI-powered analysis of Beam Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 7, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for BEAM (Beam Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.